• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    12/28/22 12:32:24 PM ET
    $HOTH
    $HTGM
    $JNCE
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HOTH alert in real time by email

    Gainers

    • Kala Pharmaceuticals (NASDAQ:KALA) shares moved upwards by 314.3% to $16.24 during Wednesday's regular session. Trading volume for this security as of 12:30 EST is 35.1 million, which is 16849.9% of its average full-day volume over the last 100 days. The company's market cap stands at $24.6 million.
    • Minerva Surgical (NASDAQ:UTRS) shares moved upwards by 74.83% to $0.28. As of 12:30 EST, Minerva Surgical's stock is trading at a volume of 23.2 million, which is 9788.1% of its average full-day volume over the last 100 days. The company's market cap stands at $8.2 million.
    • Jounce Therapeutics (NASDAQ:JNCE) stock increased by 39.67% to $1.03. The current volume of 30.7 million shares is 4872.3% of Jounce Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $53.2 million.
    • Hoth Therapeutics (NASDAQ:HOTH) stock moved upwards by 35.83% to $4.17. Trading volume for this security as of 12:30 EST is 434.0K, which is 445.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.4 million.
    • Relmada Therapeutics (NASDAQ:RLMD) stock moved upwards by 17.36% to $3.38. Trading volume for Relmada Therapeutics's stock is 192.2K as of 12:30 EST. This is 14.5% of its average full-day volume over the last 100 days. The company's market cap stands at $101.7 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares rose 16.99% to $0.47. As of 12:30 EST, this security is trading at a volume of 288.2K shares, making up 9.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.1 million.

    Losers

    • Unicycive Therapeutics (NASDAQ:UNCY) stock declined by 32.8% to $0.45 during Wednesday's regular session. Trading volume for Unicycive Therapeutics's stock is 7.7 million as of 12:30 EST. This is 23258.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.7 million.
    • Quotient (NASDAQ:QTNT) stock declined by 32.44% to $0.25. As of 12:30 EST, Quotient's stock is trading at a volume of 1.7 million, which is 237.6% of its average full-day volume over the last 100 days.
    • Minerva Neurosciences (NASDAQ:NERV) stock fell 32.34% to $1.59. Minerva Neurosciences's stock is trading at a volume of 262.5K shares as of 12:30 EST. This is 84.9% of its average full-day volume over the last 100 days. The company's market cap stands at $8.4 million.
    • Virax Biolabs Group (NASDAQ:VRAX) stock fell 16.69% to $0.57. Trading volume for Virax Biolabs Group's stock is 287.3K as of 12:30 EST. This is 23.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.3 million.
    • Exicure (NASDAQ:XCUR) stock fell 15.33% to $1.05. Exicure's stock is trading at a volume of 67.5K shares as of 12:30 EST. This is 31.2% of its average full-day volume over the last 100 days. The company's market cap stands at $5.2 million.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) stock fell 15.09% to $3.66. As of 12:30 EST, HTG Molecular Diagnostics's stock is trading at a volume of 1.2 million, which is 128.5% of its average full-day volume over the last 100 days. The company's market cap stands at $3.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $HOTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOTH
    $HTGM
    $JNCE
    $KALA

    CompanyDatePrice TargetRatingAnalyst
    Relmada Therapeutics Inc.
    $RLMD
    3/24/2026$12.00Overweight
    Piper Sandler
    Relmada Therapeutics Inc.
    $RLMD
    1/23/2026$8.00Outperform
    Leerink Partners
    Relmada Therapeutics Inc.
    $RLMD
    12/22/2025$69.00Buy
    Jefferies
    Relmada Therapeutics Inc.
    $RLMD
    11/19/2025$10.00Neutral → Outperform
    Mizuho
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    KALA BIO Inc.
    $KALA
    9/8/2025$30.00Outperform
    Mizuho
    More analyst ratings

    $HOTH
    $HTGM
    $JNCE
    $KALA
    SEC Filings

    View All

    SEC Form 144 filed by Minerva Neurosciences Inc

    144 - Minerva Neurosciences, Inc. (0001598646) (Subject)

    3/31/26 5:00:11 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Minerva Neurosciences Inc

    144 - Minerva Neurosciences, Inc. (0001598646) (Subject)

    3/31/26 4:57:35 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Minerva Neurosciences Inc

    144 - Minerva Neurosciences, Inc. (0001598646) (Subject)

    3/31/26 4:57:04 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    $HTGM
    $JNCE
    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Relmada Therapeutics with a new price target

    Piper Sandler initiated coverage of Relmada Therapeutics with a rating of Overweight and set a new price target of $12.00

    3/24/26 8:50:23 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners resumed coverage on Relmada Therapeutics with a new price target

    Leerink Partners resumed coverage of Relmada Therapeutics with a rating of Outperform and set a new price target of $8.00

    1/23/26 8:21:07 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Relmada Therapeutics with a new price target

    Jefferies initiated coverage of Relmada Therapeutics with a rating of Buy and set a new price target of $69.00

    12/22/25 8:39:56 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    $HTGM
    $JNCE
    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

    Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivat

    3/31/26 4:05:00 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

    Technology Selectively Shuts Down Cancer Reproducing CellsPatent Covers Splice-Switching Oligonucleotide Platform Designed to Induce Apoptosis of Mast CellsNEW YORK, March 31, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that the China National Intellectual Property Administration (CNIPA) has granted Chinese Patent, titled "Targeting Kit with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells." The patent, originally filed

    3/31/26 8:07:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

    LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029. Highlights:Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic (

    3/31/26 7:34:00 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HOTH
    $HTGM
    $JNCE
    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Traversa Sergio bought $113,300 worth of shares (27,500 units at $4.12), increasing direct ownership by 2% to 1,300,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:49 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Shenouda Maged bought $48,060 worth of shares (11,665 units at $4.12), increasing direct ownership by 1% to 800,000 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    12/16/25 9:30:24 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Kelly Paul Edward bought $198,000 worth of shares (90,000 units at $2.20), increasing direct ownership by 22% to 502,295 units (SEC Form 4)

    4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)

    11/6/25 7:30:02 AM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    $HTGM
    $JNCE
    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Haight Nelson M

    3 - Virax Biolabs Group Ltd (0001885827) (Issuer)

    3/31/26 3:15:09 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Mccracken Nigel William

    3 - Virax Biolabs Group Ltd (0001885827) (Issuer)

    3/20/26 10:43:07 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Foster James Alexander Cunliffe

    3 - Virax Biolabs Group Ltd (0001885827) (Issuer)

    3/18/26 4:05:23 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $HOTH
    $HTGM
    $JNCE
    $KALA
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    $HTGM
    $JNCE
    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:01:14 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOTH
    $HTGM
    $JNCE
    $KALA
    Financials

    Live finance-specific insights

    View All

    Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

    Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D

    3/30/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

    Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profileCompleted an oversubscribed $160 million PIPE financing led by leading healthcare investors in March 2026, strengthens balance sheet to support NDV-01 Phase 3 developmentOn track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026Cash balance of $93.0 million as of December 31, 2025, plus gross proceeds of $160 million from March 2026 PIPE expected to fund operations through 2029, including comple

    3/19/26 4:01:00 PM ET
    $RLMD
    Biotechnology: Pharmaceutical Preparations
    Health Care